BTIG tells investors that Lucid Diagnostics (LUCD) management tells the firm that the company’s flagship EsoGuard test is about to receive Medicare coverage. The firm, which would be buyers of the shares ahead of this catalyst as they do not believe Medicare coverage is priced into the stock, reiterates a Buy rating and $2 price target on Lucid shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUCD:
- Lucid Diagnostics’ Potential Medicare Coverage for EsoGuard Boosts Buy Rating
- Lucid Diagnostics management to meet virtually with BTIG
- Lucid Diagnostics Holds Annual Stockholders Meeting
- Lucid Diagnostics price target raised to $7.75 from $7.50 at Ascendiant
- Lucid Diagnostics Enters $25M Sales Agreement